Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 308
- Registration Number
- NCT02254291
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT02249910
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT02249871
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT02243098
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT02231684
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 87
- Registration Number
- NCT02212067
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
- Conditions
- Interventions
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2017-12-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 44
- Registration Number
- NCT02210871
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 601
- Registration Number
- NCT02207374
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT02172313
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT02161588
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.